Coya Therapeutics, Inc.

NASDAQ:COYA

Biotechnology

Healthcare
$3.09 -3.18%

-$0.16 today

Market cap
$72.48M
Beta
0.62
P/E (TTM)
-3.9
EPS (TTM)
-$1.26
52W Low $3.71High $7.75

Volume 0.15M

Average 0.16M

COYA Common Stock Repurchased

Cash spent buying back the company's own shares.

Coya Therapeutics, Inc.NASDAQ: COYA

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased outflow grows to $0

Q1 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How COYA compares with its peers on the latest reported figures

  • COYA's LTM Mar 2026 common stock repurchased of $0 is the 2nd largest of the 11 companies compared; the peer median is $0.
  • Common stock repurchased amounts to 0.0% of revenue for COYA, versus a peer median of 0.0%.
COYA Competitors Peer median
Common Stock Repurchased for COYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$4.77M +92.2%——
COYACoya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
IMMXImmix Biopharma, Inc.LTM Mar 2026$0 ———
OVIDOvid Therapeutics Inc.LTM Mar 2026$0 ——0.0%
STTKShattuck Labs, Inc.LTM Mar 2026$0 +100.0%—0.0%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$0 ——0.0%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 ———
MGNXMacroGenics, Inc.LTM Mar 2026$0 ——0.0%
CLNNClene Inc.LTM Mar 2026$0 ——0.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 ———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 +100.0%——
Peer median (excluding COYA) $0+100.0%—0.0%

Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(4.89M)(12.24M)(7.99M)(14.88M)(21.23M)
Depreciation & Amortization16.13K27.36K27.36K27.36K27.36K
Deferred Income Tax399.68K0000
Stock-Based Compensation233.22K207.35K872.25K2.66M4.29M
Change in Working Capital739.17K751.84K(4.64M)1.88M3.88M
Accounts Receivables00(7.5M)7.5M0
Inventory00000
Accounts Payables665.17K845.28K298.82K477.45K(527.01K)
Other Working Capital74K(93.45K)2.56M(6.1M)4.41M
Other Non-Cash Items(399.68K)4.02M543.19K25K2.29M
Operating Cash Flow(3.9M)(7.24M)(11.19M)(10.29M)(10.74M)
Capital Expenditures(136.8K)0000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(525K)(543.19K)(25K)0
Investing Cash Flow(136.8K)(525K)(543.19K)(25K)(1.16M)
Debt Repayment010.47M000
Common Stock Issued1.32K15838.34M14M20.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(341.9K)(1.11M)89.95K2.02M0
Financing Cash Flow(340.58K)9.36M38.43M16.03M20.39M
Effect of Forex Changes00000
Net Change in Cash(4.38M)1.59M26.69M5.71M8.48M
Free Cash Flow(4.04M)(7.24M)(11.19M)(10.29M)(10.74M)

Coya Therapeutics, Inc.

NASDAQ:COYA

Intrinsic Alpha fair value

Locked

Current Price

$3.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.